PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma

Rekrutierend

NCT-Nummer:
NCT04099134

Studienbeginn:
Oktober 2018

Letztes Update:
25.09.2019

Wirkstoff:
-

Indikation (Clinical Trials):
Adenocarcinoma, Pancreatic Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University of Ulm

Collaborator:
-

Studienleiter

Thomas Seufferlein, MD
Principal Investigator
Ulm University Hospital

Kontakt

Thomas Seufferlein, MD
Kontakt:
Phone: +49 731 50044501
E-Mail: thomas.seufferlein@uniklinik-ulm.de» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Leberkrebszentrum Universitätsklinikum Ulm
Albert-Einstein-Allee 23
89081 Ulm
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Thomas Seufferlein, MD
Phone: 0049-731-500-44501
E-Mail: thomas.seufferlein@uniklinik-ulm.de» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

PaCaReg is a multicenter registry trial aiming in the assessement of clinical,

epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Treatment naive histologically or cytologically proven pancreatic ductal

adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended

resection)

- Age =>18 years

- written informed consent

Exclusion Criteria:

- papillary cancer

- neuroendocrine pancreatic tumors

Studien-Rationale

Primary outcome:

1. General assessment of applied therapy modalities in pancreatic cancer (Time Frame - First diagnose to death or end of surveillance (5 years after curative resection))

2. Quality of life in pancreatic cancer patients (Time Frame - First diagnose to death or end of surveillance (5 years after curative resection)):
EORTC QLQ c30 and PAN 26

Secondary outcome:

1. General epidemiologic assessment (Time Frame - First diagnose to death or end of surveillance (5 years after curative resection)):
Epidemiologic questionaire

2. Assessment of tumor surveillance in pancreatic cancer patients (Time Frame - First diagnose to death or end of surveillance (5 years after curative resection))

3. Evaluation of predictive and prognostic markers (Time Frame - First diagnose to death or end of surveillance (5 years after curative resection))

Quelle: ClinicalTrials.gov